3,328 Shares in Medtronic plc (NYSE:MDT) Purchased by Certior Financial Group LLC

Certior Financial Group LLC purchased a new stake in shares of Medtronic plc (NYSE:MDT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 3,328 shares of the medical technology company’s stock, valued at approximately $266,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MDT. Morse Asset Management Inc bought a new stake in shares of Medtronic during the 3rd quarter worth $225,000. Quadrature Capital Ltd bought a new position in shares of Medtronic during the 3rd quarter valued at about $252,000. Two Sigma Advisers LP raised its holdings in shares of Medtronic by 131.2% during the 3rd quarter. Two Sigma Advisers LP now owns 333,220 shares of the medical technology company’s stock valued at $30,000,000 after buying an additional 189,088 shares in the last quarter. Kovitz Investment Group Partners LLC lifted its position in Medtronic by 27.0% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 106,289 shares of the medical technology company’s stock worth $8,750,000 after buying an additional 22,621 shares during the last quarter. Finally, EP Wealth Advisors LLC boosted its stake in Medtronic by 31.2% in the third quarter. EP Wealth Advisors LLC now owns 16,080 shares of the medical technology company’s stock worth $1,448,000 after buying an additional 3,825 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on MDT shares. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research note on Wednesday, February 19th. Robert W. Baird lifted their target price on shares of Medtronic from $90.00 to $91.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Truist Financial cut their price target on shares of Medtronic from $93.00 to $89.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. UBS Group lifted their price objective on Medtronic from $85.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $105.00 target price on shares of Medtronic in a report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Hold” and a consensus price target of $96.07.

Insider Buying and Selling

In other Medtronic news, EVP Brett A. Wall sold 9,850 shares of the business’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $80.41, for a total value of $792,038.50. Following the sale, the executive vice president now directly owns 40,708 shares of the company’s stock, valued at approximately $3,273,330.28. The trade was a 19.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.20% of the stock is owned by company insiders.

Medtronic Price Performance

MDT stock opened at $82.86 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39. Medtronic plc has a 1 year low of $75.96 and a 1 year high of $96.25. The firm has a 50-day moving average of $90.87 and a 200 day moving average of $87.93. The company has a market cap of $106.28 billion, a P/E ratio of 25.19, a PEG ratio of 2.22 and a beta of 0.79.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.03. The company had revenue of $8.29 billion during the quarter, compared to analysts’ expectations of $8.33 billion. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. On average, sell-side analysts forecast that Medtronic plc will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 11th. Investors of record on Friday, March 28th will be paid a $0.70 dividend. The ex-dividend date is Friday, March 28th. This represents a $2.80 annualized dividend and a dividend yield of 3.38%. Medtronic’s payout ratio is 85.11%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.